Group 1 - The primary attraction for investors in Pfizer is its high dividend yield of 7.2%, significantly higher than the S&P 500's 1.2% and the average pharmaceutical stock's 1.3% [1] - Pfizer has a strong history of survival in the competitive pharmaceutical sector, boasting a market capitalization of $135 billion and over 100 years of operation [2] - The company has a track record of investing in new drug development and has also engaged in acquisitions to enhance its drug pipeline, as evidenced by its recent agreement to acquire Metsera for approximately $4.9 billion [3][4] Group 2 - Despite the attractive dividend yield, Pfizer faces challenges, particularly a looming patent cliff that could impact its revenue [5][6] - Key drugs such as Ibrance, Eliquis, and Vyndaqel are set to lose patent protections between 2027 and 2028, prompting Pfizer to strengthen its drug pipeline through acquisitions like Metsera [7] - The company's high dividend payout ratio raises concerns about the sustainability of its dividend amidst these challenges [8]
3 Things You Need to Know if You Buy Pfizer Today
Yahoo Financeยท2025-10-02 11:02